Dear Ms. Price:

Please refer to your supplemental new drug application dated March 14, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Diovan (valsartan) 40, 80, 160, and 320 mg Tablets.

This “Changes Being Effected” supplemental new drug application provides for electronic final printed labeling revised as follows:

1. Under the “WARNINGS/Fetal/Neonatal Morbidity and Mortality” subsection, the following was added as the third sentence of the first paragraph:

   There have been reports of spontaneous abortion, oligohydramnios and newborn renal dysfunction when pregnant women have inadvertently taken valsartan.

2. Under the “ADVERSE REACTIONS/Post-Marketing Experience” subsection, the following subheading and text were added:

   **Blood and Lymphatic:** There are very rare reports of thrombocytopenia.

3. Under the “OVERDOSAGE” section, the following was added as the third sentence of the first paragraph:

   Depressed level of consciousness, circulatory collapse and shock have been reported.

In addition, the following minor editorial change was noted:

   The issue date at the end of the package insert has been updated so that it now reads:

   REV: MARCH 2006

We have completed our review of this supplemental new drug application and it is approved, effective on the date of this letter, for use as recommended in the electronic labeling submitted on March 14, 2006.

We note that in the Structured Product Labeling (SPL) version of this submission, under the “CLINICAL PHARMACOLOGY/Pharmacodynamics and Clinical Effects/Post-Myocardial Infarction” subsection, the title “Effects on Mortality Amongst Subgroups in VALIANT” is missing from the last table. Please re-add this title to the table in future SPL versions you submit.
At the time of your next printing, please make the following minor editorial corrections:

Under the “WARNINGS/Fetal/Neonatal Morbidity and Mortality” subsection, delete the word “inadvertently” from the third sentence of the first paragraph so that it reads:

There have been reports of spontaneous abortion, oligohydramnios and newborn renal dysfunction when pregnant women have taken valsartan.

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH  
Food and Drug Administration  
WO 22, Room 4447  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please contact:

Quynh Nguyen, Pharm.D.  
Regulatory Health Project Manager  
(301) 796-0510

Sincerely,

{See appended electronic signature page}

Norman Stockbridge, M.D., Ph.D.  
Director  
Division of Cardiovascular and Renal Products  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Norman Stockbridge
11/22/2006 08:13:59 AM